Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Next-generation Sequencing03:00

Next-generation Sequencing

99.9K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
99.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantifying Formation Permeability Effects on High-Temperature Aquifer Thermal Energy Storage.

ACS omega·2026
Same author

Unspecific Peroxygenase Catalyzed Benzylic C-H Functionalization of di<i>N</i>-Heterocycles and Its Application.

Organic letters·2026
Same author

Association between pre-diagnostic prevalence of 30 common diseases and the subsequent risk of dementia: a population-based retrospective cohort study in Taiwan.

Frontiers in aging neuroscience·2026
Same author

Modified Erxian Decoction ameliorates premature ovarian insufficiency via HIF-1α-mediated regulation of mitochondrial fission and oxidative stress.

Journal of ethnopharmacology·2026
Same author

Multicentre gene therapy for OTOF-related deafness followed up to 2.5 years.

Nature·2026
Same author

Si-Ni-San alleviates depressive-like behaviors in adolescent male mice by restoring DRN-NAc serotonergic circuit function and 5-HT4R-dependent synaptic plasticity.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026

Related Experiment Video

Updated: Mar 7, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K

Next-generation sequencing for DLBCL patients with early failure after frontline R-CHOP chemo-immunotherapy.

Liu Shi1,2, Xiaohua Liu1,2, Jing Wang1,2

  • 1Department of Radiation Oncology, Jiangxi Cancer Hospital of Nanchang Medical College, Nanchang, China.

Frontiers in Oncology
|March 6, 2026
PubMed
Summary

Early treatment failure in Diffuse large B-cell lymphoma (DLBCL) is linked to specific gene mutations and lack of complete response. Identifying these factors can guide alternative therapy development for better patient outcomes.

Keywords:
DLBCLdiffuse large B-cell lymphomaearly failureinterim treatment responsesnext-generation sequencing

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.6K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Experiment Videos

Last Updated: Mar 7, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.6K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Diffuse large B-cell lymphoma (DLBCL) patients experiencing early treatment failure (POD12) within 12 months of R-CHOP chemo-immunotherapy face poor outcomes.
  • Identifying predictive biomarkers for early treatment failure is crucial for developing alternative therapeutic strategies.

Purpose of the Study:

  • To investigate the association between gene alterations and clinical factors with early treatment failure (POD12) in newly diagnosed DLBCL patients.
  • To understand the molecular landscape associated with treatment resistance in DLBCL.

Main Methods:

  • Next-generation sequencing was used to analyze gene alterations in 103 genes across 26 newly diagnosed DLBCL patients treated with R-CHOP.
  • Clinical factors and gene mutation data were analyzed for their association with early progression (POD12).

Main Results:

  • Patients with POD12 exhibited significantly poorer overall survival (OS) (HR=12.13, p=0.0029).
  • Mutations in epigenetic modulation and apoptosis/cell cycle/autophagy pathways were prevalent in the POD12 group.
  • CD79B mutations were significantly higher in the no-POD12 group (50% vs 8.33%, p=0.0357), while wild-type CD79B was associated with POD12.
  • Failure to achieve complete response (CR) during interim evaluation strongly correlated with POD12 (p=0.0214).

Conclusions:

  • Wild-type CD79B and failure to achieve interim CR are significant indicators of early treatment failure (POD12) in DLBCL.
  • These findings support the development of targeted alternative therapies for DLBCL patients identified as high-risk for early progression.